Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

Also called NCT05369975

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 113 participants (enrolled count) (from the registry)
Sponsor
Hansa Biopharma AB (from the registry)
Registry
  • NCT NCT05369975
  • EudraCT 2021-002640-70
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Slovenia, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05369975. Non-randomized; no masking; primary purpose treatment. Start 2022-04-19 (actual); primary completion 2026-04-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Acronym
PAES
Condition
Kidney Transplantation in Highly Sensitized Patients
Intervention (Drug)
Imlifidase
Intervention (Other)
Normal Transplantation Routine
Lead sponsor
Hansa Biopharma AB (class: industry)

Record details

Record id
cardio:ct-nct05369975
Content hash
1b3d6b465226546b122bf1c1ff3da1c0b9b555861651e93adb44df16203f7018